Drug Type Small molecule drug |
Synonyms MLN-7243, TAK 243 |
Target |
Mechanism UBA1 inhibitors(Ubiquitin-like modifier-activating enzyme 1 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H20F3N5O5S2 |
InChIKeyKJDAGXLMHXUAGV-DGWLBADLSA-N |
CAS Registry1450833-55-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Myelomonocytic Leukemia | Phase 1 | - | 30 Aug 2024 | |
Refractory acute myeloid leukemia | Phase 1 | - | 30 Aug 2024 | |
refractory chronic myelocytic leukemia | Phase 1 | - | 30 Aug 2024 | |
Refractory High Risk Myelodysplastic Syndrome | Phase 1 | - | 30 Aug 2024 | |
Refractory Myelodysplastic Syndrome | Phase 1 | - | 30 Aug 2024 | |
Relapsing acute myeloid leukemia | Phase 1 | - | 30 Aug 2024 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 31 Jan 2014 |
Phase 1 | 29 | (Schedule A: TAK-243 1 mg) | vyocpmeakw(qrwxawhaqv) = ripszzhypl gulxlxnrrp (bpywwzwlds, onzlredcgt - apuhclguuo) View more | - | 14 Mar 2019 | ||
(Schedule A: TAK-243 2 mg) | vyocpmeakw(qrwxawhaqv) = fkbdffsqzo gulxlxnrrp (bpywwzwlds, oqpggyygtr - jqjocweqgr) View more |